Orthopedics This Week5d
3- and 6-Month RCT Data for Novel Nerve Stim Treatment
The resulting paper, “ Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain ...
FierceBiotech12d
Rapport's attempt to test epilepsy drug in nerve damage placed on hold by FDA
The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...
GlobalData on MSN11d
Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain
Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...
Business Wire1d
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...
Daily21h
Pregabalin Significantly Reduces Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa: JAMA
Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...
GlobalData on MSN4d
Tivic hits enrolment target for vagus nerve stimulation trial
"Tivic hits enrolment target for vagus nerve stimulation trial" was originally created and published by Medical Device ...
The Victoria Advocate13d
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
"By adding post-surgical neuropathic pain to the U.S. label if results ... in all controlled clinical trials are application site erythema, application site pain, and application site pruritus.